Flashback Foreword: Chemoradiotherapy for Nasopharyngeal Carcinoma

Article Tools FLASHBACK FOREWORD Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.. August 16, 2023 ARTICLE CITATION DOI: 10.1200/JCO.23.00932 Journal of Clinical Oncology - published online before print August 16, 2023 PMID: 37586208 Flashback Foreword: Chemoradiotherapy for Nasopharyngeal Carcinoma Maura L. Gillison, MD, PhD1,2xMaura L. GillisonSearch for articles by this author Show More 1Associate Editor, Journal of Clinical Oncology, Alexandria, VA2MD Anderson, Houston, TX https://doi.org/10.1200/JCO.23.00932 First Page Full Text PDF Figures and Tables © 2023 by American Society of Clinical OncologyTHE TAKEAWAYIn 1998, Al-Sarraf et al1 reported significant improvements in overall and progression-free survival for patients with locoregionally advanced nasopharyngeal carcinoma when concurrent and adjuvant cisplatin-based chemotherapy was added to radiation therapy. The trial immediately changed the standard of care but raised numerous questions regarding the relative contributions of concurrent versus adjuvant chemotherapy.AUTHOR'S DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTFlashback Foreword: Chemoradiotherapy for Nasopharyngeal CarcinomaThe following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Maura L. GillisonThis author is an Associate Editor for Journal of Clinical Oncology. Journal policy recused the author from having any role in the peer review of this manuscript.Consulting or Advisory Role: Bristol Myers Squibb, Merck, EMD Serono, BioNTech, Shattuck Labs, Bayer, Debiopharm Group, Ipsen, Gilead Sciences, Bicara Therapeutics, BioNTech, Nektar, Istari, LLX Solutions, OncLive, Seagen, Kura Oncology, Mirati Therapeutics, Sensei Biotherapeutics, Eisai, Exelixis, ITeos Therapeutics, Caladrius Biosciences, Coherus BiosciencesResearch Funding: Bristol Myers Squibb (Inst), Genocea Biosciences (Inst), Cullinan Oncology (Inst), Genentech (Inst), Agenus (Inst), Kura Oncology (Inst), Seagen (Inst)No other potential conflicts of interest were reported. Companion Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.